Dr. Bianchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2016
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2009 - 2012
- Universita San RaffaeleClass of 2006
Certifications & Licensure
- MA State Medical License 2012 - 2025
- MN State Medical License 2011 - 2012
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsElotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
Blood Advances. 2025-03-11 - 1 citationsThe dynamics of hematopoiesis over the human lifespan.Hojun Li, Parker Côté, Michael Kuoch, Jideofor Ezike, Katie Frenis
Nature Methods. 2025-02-01 - Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.Omar Nadeem, Michelle P Aranha, Robert Redd, Michael Timonian, Sophie Magidson
Nature Communications. 2025-01-03
Abstracts/Posters
- Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple MyelomaGiada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaGiada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical ApplicationGiada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
- The Economic Effects of the Coronavirus May Kill More Americans Than the Virus ItselfJanuary 25th, 2021
- Administered Earlier, Cilta-Cel CAR T Produces Deep, Durable Responses in Multiple Myeloma PatientsDecember 9th, 2023
Grant Support
- Functional Consequences of Ubiquitin Depletion During B Lymphocyte DifferentiationBRIGHAM AND WOMEN'S HOSPITAL2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: